CEDIRANIB

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H27FN4O3
Molecular Weight	450.5053
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=C(OCCCN2CCCC2)C=C3N=CN=C(OC4=C(F)C5=C(NC(C)=C5)C=C4)C3=C1

InChI

InChIKey=XXJWYDDUDKYVKI-UHFFFAOYSA-N

InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C25H27FN4O3
Molecular Weight	450.5053
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Cediranib (AZD-2171) is a VEGFR-2 kinase inhibitor which was developed by AstraZeneca for the treatment of cancer. The drug reached the final stage of approval by European Medicines Agency in 2008 under the name Zemfirza (it was recommended to be taken in combination with platinum-based chemotherapy), however on 19 September 2016 AstraZeneca decided to withdraw the Marketing Authorisation Application.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Vascular endothelial growth factor receptor 2 104	Inhibitor 8,297		1.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Ovarian cancer 157	Primary	Phase III 656	Unknown
Fallopian tube cancer 17	Primary	Phase III 656	Unknown
Primary peritoneal cancer 3	Primary	Phase III 656	Unknown

PubMed

Show entries

Title	Date	PubMed
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.	2007 Jan	17222792
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.	2007 May 15	17505008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.	2008 Apr 10	18398152
Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.	2008 Dec	19075590
Targeting angiogenesis in the treatment of lung cancer.	2008 Oct	18827616

Showing 1 to 5 of 19 entries

Previous1 2 3 4Next

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dose is 20 mg taken orally, once daily.

Route of Administration: Oral

In Vitro Use Guide

NCI-H526 cells were treated with Cediranib for 72 hours (0.001 nM, 0.01 nM, 0.1 nM, 1 nM, 10 nM, 100 nM). Cediranib inhibited SCF-stimulated proliferation of cells with an IC50 value of 0.013 nmol/L.